Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Rifadin, Rifampin injection (Special Access Program)
Rifamycin Antibiotic, Antituberculous Agent
Original Date: 
June 1996
Revised Date: 
May 2010
  • Straphylococcal infections resistant to first line antibiotics normally proven effective. To prevent the emergence of resistant bacteria, rifampin must always be combined with other antibiotics
  • IV intermittent infusion: over 1 hour
  • PO
  • 10-20 mg/kg/day IV/PO once daily or divided Q12H


Side Effects: 
  • Dermatologic: occasional flushing
  • GI: vomiting, diarrhea
  • Hematologic: thrombocytopenia, leukopenia, hemolytic anemia, decreased hemoglobin

  • Hepatic: transient abnormalities in LFTs
  • Other: may cause red discolouration e.g., urine, sputum
  • Renal: elevations in urea and serum uric acid
Parameters to Monitor: 
  • CBC, platelet count
  • LFTs during prolonged therapy
Reconstitution and Stability: 

IV Intermittent infusion:

  • Rifampin 600 mg (Emergency release)
  • Reconstitute with 10 mL of SWFI (60 mg/mL). Take 1 mL (60 mg) and add to 9 mL D5W (vial)
  • Final concentration: 6 mg/mL

  • Stable for 4 hours



- Solutions Compatible: dextrose, 0.9% NaCl

- Y-site Compatible: gentamicin

Incompatible: sodium bicarbonate, TPN


- Lau E. (Editor). Drug Handbook and Formulary - The Hospital for Sick Children. Toronto; 2009-2010

- Taketomo CK, Hodding JH, Kraus DM.  Pediatric Dosage Handbook 16th Edition. Hudson: Lexi-Comp Inc.; 2009

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.